Mesothelioma Treatment in New York

Top Mesothelioma Centers in New York

The best New York mesothelioma cancer centers include university hospitals, research centers and NCI-Designated Comprehensive Cancer Centers. At New York University’s Langone Health Perlmutter Cancer Center, specialists coordinate innovative clinical trials for thoracic cancers. Thoracic surgeon Dr. Andrea Wolf at the NCI-Designated Mount Sinai Tisch Cancer Center launched a groundbreaking mesothelioma vaccine clinical trial in 2022.

At the Roswell Park Comprehensive Cancer Center in Buffalo, a team of cancer specialists work together to develop the patient’s treatment plan. This multidisciplinary approach can improve the quality of treatment, patient care and follow-up support.

Mount Sinai Hospital

1 Gustave L. Levy Pl New York, NY 10029

Perlmutter Cancer Center

160 E. 34th St New York, NY 10016

Roswell Park Cancer Institute, mesothelioma cancer center in Buffalo, NY

Roswell Park Comprehensive Cancer Center

120 Carlton St, Buffalo, NY 14203, USA

Maimonides Medical Center

4802 10th Ave, Brooklyn, New York 11219

Locations of New York’s Top Cancer Centers

5 New York mesothelioma cancer centers are located in or near New York City, including the Herbert Irving Comprehensive Cancer Center at Columbia University. On the other hand, mesothelioma patients who live in Upstate New York can visit Roswell Park Comprehensive Cancer Center in Buffalo. Roswell Park has surgeons that specialize in peritoneal and pleural mesothelioma. The Wilmot Cancer Institute at the University of Rochester is also an NCI-Designated Cancer Center in Upstate New York.

All Centers (6)

Maimonides Medical Center
4802 10th Ave
Brooklyn, NY 11219

Directions
Mount Sinai Hospital
1 Gustave L. Levy Pl
New York, NY 10029
- Center of Excellence
Directions
New York-Presbyterian Hospital/Columbia University Medical Center
630 W 168th St
New York, NY 10032
- NCI-Designated Cancer Center
Directions
Perlmutter Cancer Center
160 E 34th St
New York, NY 10016
- NCI-Designated Cancer Center
Directions
Roswell Park Comprehensive Cancer Center
120 Carlton St
Buffalo, NY 14203
- NCI-Designated Cancer Center
Directions
Stony Brook Cancer Center
101 Nicolls Road
Stony Brook, NY 11794

Directions

Top Doctors in New York

The best mesothelioma doctors in New York specialize in peritoneal or pleural mesothelioma, lead clinical research or use cutting-edge techniques, such as robotic or video-assisted thoracic surgery. Depending on the patient’s diagnosis, mesothelioma treatment can require a radiation oncologist, pulmonary specialist, thoracic surgeon or another specialist, which is why multidisciplinary teams are so valuable.

One of the top pleural mesothelioma doctors in New York is Dr. Raja Michael Flores, a thoracic surgeon and mesothelioma specialist at Mount Sinai Hospital who pioneered a gold-standard, minimally invasive procedure for pulmonary cancers. The Director of the Mesothelioma Program at Mount Sinai is Dr. Andrea Wolf, an expert in VATS lobectomy and other advanced surgical techniques for mesothelioma. Leading peritoneal mesothelioma doctors in New York include Dr. John M. Kane III at the Roswell Park Comprehensive Cancer Center and Dr. Zachary Brown at the Perlmutter Cancer Center.

Top New York Mesothelioma Doctors

Raja Michael Flores

Pleural Specialist | Thoracic Surgery

Expertise:

Pleural Mesothelioma Pleurectomy and Decortication Surgery Lung Cancer VATS Lobectomy Thoracotomy Clinical Research

Mount Sinai Hospital • New York, New York

View Profile

Expertise:

Pleural Mesothelioma Pleurectomy and Decortication Surgery Lung Cancer VATS Lobectomy Thoracotomy Clinical Research

Mount Sinai Hospital

New York, New York

View Profile

Dr. Raja Michael Flores is a professor and chairman of the Department of Thoracic Surgery at Mount Sinai Medical Center in New York City. Flores is a widely respected expert in pleural mesothelioma and is a recognized leader in the field of thoracic surgery for pioneering video-assisted surgical techniques for lung cancer and mesothelioma.

Read Bio

Daniel H. Sterman

Pleural Specialist | Interventional Pulmonology

Expertise:

Thoracic Diseases Minimally Invasive Procedures

Perlmutter Cancer Center • New York, New York

View Profile

Expertise:

Thoracic Diseases Minimally Invasive Procedures

Perlmutter Cancer Center

New York, New York

View Profile

Dr. Daniel H. Sternman is the director of the Multidisciplinary Pulmonary Oncology Program at NYU Langone Medical Center and a thoracic oncology expert. He is double board-certified in internal medicine and pulmonary medicine and a respected expert on pleural mesothelioma and lung cancer.

Read Bio

John M. Kane III

Peritoneal Specialist | Surgical Oncology

Expertise:

Cytoreductive Surgery HIPEC

Roswell Park Comprehensive Cancer Center • Buffalo, New York

View Profile

Expertise:

Cytoreductive Surgery HIPEC

Roswell Park Comprehensive Cancer Center

Buffalo, New York

View Profile

Surgical oncologist Dr. John Kane III treats patients with peritoneal surface malignancies, including mesothelioma, at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

Read Bio

Daniel M. Labow

Peritoneal Specialist | Surgical Oncology

Expertise:

Cytoreductive Surgery HIPEC

Praxair Cancer Center at Danbury Hospital • Danbury, Connecticut

View Profile

Expertise:

Cytoreductive Surgery HIPEC

Praxair Cancer Center at Danbury Hospital

Danbury, Connecticut

View Profile

Surgeon Dr. Daniel M. Labow is an advocate of hyperthermic intraperitoneal chemotherapy for patients with peritoneal mesothelioma, and started the HIPEC program at Mount Sinai Medical Center.

Read Bio

Find a Specialist Near You

Begin your search for a doctor in your area.

Get started by selecting location, type, specialty or language.

Type of Mesothelioma

Specialty

Language

Clinical Trials in New York

Research hospitals and cancer centers across New York regularly participate in innovative mesothelioma clinical trials, such as research on CAR T-cell therapy. Speak to your mesothelioma doctor or a Patient Advocate to learn more about clinical trials currently enrolling at places like the Mount Sinai Tisch Cancer Center in NYC. Trials may provide early access to state-of-the-art treatment options.

NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Locations

NCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Locations

NCT06477419

A Study of Sacituzumab Govitecan in People With Mesothelioma

Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.

Locations

NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Locations

NCT05732831

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Locations

NCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.

Locations

NCT04665206

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Locations

NCT06057935

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Locations

NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Locations

NCT07532902

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.

Locations

NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose

Locations

NCT06037941

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Locations

NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Locations

NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Locations

Financial Support for Treatment in New York

Many financial aid programs are available to mesothelioma patients who live in New York and need help with day-to-day expenses, travel costs, medical insurance and treatment costs. Charities like the New York Cancer Foundation offer emergency financial aid. Others provide free support services for cancer patients and family members.

As nonprofits, many New York cancer centers must follow state “Charity Care” laws aimed to help patients who can’t pay their medical bills. Families struggling to cover the costs of mesothelioma treatment in New York can apply for discounts of up to 100% on medical bills.

Financial Aid in New York

CancerCare: CancerCare financial aid programs can help cancer patients anywhere in New York with basic needs such as home care, child care and pet assistance. For mesothelioma patients, the New York nonprofit can cover the costs of lodging and air or car transportation for treatments in the city.
CancerConnects: Located in East Syracuse, CancerConnects provides financial support programs for cancer patients in Central and Northern New York. Eligible families can receive a one-time Angel Fund grant of up to $500 for medical expenses, insurance premiums or co-payments, medication, food, transportation costs and some day-to-day needs.
Magnolia Meals at Home: Mesothelioma patients in Westchester County and other parts of New York can benefit from this nonprofit meal delivery program. Magnolia volunteers deliver nutritious free meals to cancer patients. Eligible families receive up to 40 meals over 2 months.
Memorial Sloan Kettering Cancer Center: This leading treatment center for peritoneal and pleural mesothelioma can help patients who have trouble affording the necessary care. The center’s Patient Financial Services team also helps patients apply for prescription discounts that are sometimes available from manufacturers.
New York Cancer Foundation: Located in Shirley on Long Island, the New York Cancer Foundation offers short-term aid for cancer patients living in the state. The emergency assistance programs don’t apply to medical treatment, but they can cover important needs such as transportation, rent, food, utilities, car payments and other bills. In 2024, this New York nonprofit distributed nearly $1.6 million in financial aid to 745 cancer patients.
Roswell Park Comprehensive Care Center: Depending on family income, mesothelioma patients at Roswell Park may receive free care if their insurance provider refuses to cover necessary treatment. The Roswell Park Alliance Foundation supports more than 50,000 patients annually.

Patient Advocates are another valuable resource for mesothelioma patients looking for financial support programs. These professionals help families connect with local, New York-specific and national organizations offering financial aid. U.S. veterans with mesothelioma may also be eligible for VA benefits, including disability compensation and survivor benefits. Our Veterans Department’s VA-accredited claims agents can explain the approval process and help patients file claims.

Cancer Resources in New York

Many of New York’s nonprofits, state organizations and mesothelioma cancer centers offer free cancer support services, educational programs and resources. Groups such as Cancer Support Team and the Pluta Cancer Foundation can help mesothelioma patients access cancer rehabilitation therapy, nutrition support, counseling sessions, transportation assistance programs and emotional support communities. These resources can benefit newly diagnosed mesothelioma patients, cancer survivors, caregivers and family members.

Local Support Options for Mesothelioma Patients

CancerCare: CancerCare offers a variety of free 12-week programs for patients actively undergoing cancer treatment, with a focus on older adults. The organization provides information about treatments, tips for coping with anxiety and other community resources. Oncology social workers lead group sessions and offer emotional and practical support.
Cancer Support Team: Based in Westchester, Cancer Support Team offers at-home nursing care, counseling, case management and transportation services, all free of charge to cancer patients. Through donations, the nonprofit can also cover daily living costs for some patients.
Memorial Sloan Kettering: Memorial Sloan Kettering coordinates support groups and programs for cancer patients, caregivers and families. The organization’s support team includes social workers, psychiatrists, psychologists and volunteers. Online virtual programs are available for patients unable to visit the New York City location in person.
Pluta Cancer Foundation: The Pluta Cancer Foundation provides basic financial aid and support programs for cancer patients receiving treatment at the NCI-Designated Wilmot Cancer Institute in Rochester. The charity’s Integrative Oncology & Wellness Program includes free services such as acupuncture, massage, exercise classes, art therapy and consultations with a Registered Dietician.
Red Door Community: Based in New York City, Red Door Community provides educational resources, community events and workshops for mental and emotional wellness. Mesothelioma patients can schedule one-on-one counseling sessions. Surviving family members can find bereavement support groups.
Wig Clinic: Available to women undergoing chemotherapy for mesothelioma who live near New York City or Long Island, CancerCare’s Wig Clinic locations provide a free wig and a personalized fitting appointment.

New York’s 211 program is another excellent resource for mesothelioma patients, connecting local families with free services for transportation, mental health support, meals and home care for older Americans. All state regions are covered, from the Adirondacks to Albany.

What Survivors Say About Their Mesothelioma Treatment in New York

New York mesothelioma patients who have shared their stories with us have spoken about the excellent care available in the state. Pleural and peritoneal mesothelioma doctors at cancer centers like Roswell Park use cutting-edge therapies, including cytoreductive surgery with heated chemotherapy.

Survivor Experience

On her cytoreductive surgeon: “We looked him up before we went because my oncologist [in Rochester] said you have to be comfortable with your surgeon,” Darlene said. “We ended up loving him from the start.”

– Darlene M. , Peritoneal Mesothelioma Survivor

Verified Asbestos.com Survivor

Expert Insight

“Most clinical trials fail. I know that, but you’re always looking to be that one in a million. I don’t think anyone should give up hope of finding it,” Peter said. “If the trial doesn’t help you, at least it will help someone who comes after you.”

– Peter L. , Pleural Mesothelioma Survivor